These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25391703)

  • 1. Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.
    Yanagihara K; Takei H; Iida S; Yamashita K; Kurita T; Iwamoto M; Saegusa H; Uchida E
    J Nippon Med Sch; 2014; 81(5):333-6. PubMed ID: 25391703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
    Rodriguez CA; Martin T; Lozano R; Gomez A; Cruz JJ
    Breast J; 2017 Nov; 23(6):745-746. PubMed ID: 28845572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer].
    Tsubota Y; Sueoka N; Yamamoto D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1954-6. PubMed ID: 25731387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
    Okamoto A; Nakatsukasa K; Fujita Y; Sugimoto R; Sakaguchi K; Taguchi T
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):343-6. PubMed ID: 25812504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.
    Lecarpentier E; Ouaffi L; Mir O; Berveiller P; Maurel M; Pujade-Lauraine E; Bouillot JL; Veyrie N
    Invest New Drugs; 2011 Dec; 29(6):1500-3. PubMed ID: 20676743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer.
    Joerger M; Riesen WF; Thürlimann B
    J Oncol Pharm Pract; 2011 Sep; 17(3):292-4. PubMed ID: 20667851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report.
    Ishizuna K; Ninomiya J; Ogawa T; Tsuji E
    J Med Case Rep; 2014 Dec; 8():417. PubMed ID: 25491149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer.
    Cao D; Guo CH; Liu JW; Yang X; Li Q
    Tumori; 2015; 101(1):46-51. PubMed ID: 25702674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].
    Kawai H; Sugimoto R; Miyauchi S; Yoshida R; Waki N; Hirayama S; Ishizaki M; Nishi H; Yamashita K
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1957-9. PubMed ID: 25731388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
    Hardy-Bessard AC; Delva R; Pivot X; Espié M; Dalenc F; Coulon Sfairi MA; Monnier A; Serin D; Veyret C; Lortholary A; Pavlyuk M; Kockler L; Pierga JY
    Bull Cancer; 2012 Jun; 99(6):609-18. PubMed ID: 22665515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
    Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
    Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
    Mychaluk J; Piprot C; Sevestre H; Merviel P; Gondry J; Fauvet R
    Presse Med; 2009 Sep; 38(9):1370-4. PubMed ID: 19349140
    [No Abstract]   [Full Text] [Related]  

  • 14. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of stage IV breast cancer with improved cancer pain using bevacizumab and paclitaxel].
    Ishiyama T; Jinguu A; Matsumoto H; Kikuchi J; Suzuki T
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):347-9. PubMed ID: 25812505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
    Suzuki S; Sakurai K; Nagashima S; Hara Y; Amano S; Enomoto K; Makishima M
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1289-91. PubMed ID: 25335720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
    Aomatsu N; Kashiwagi S; Morisaki T; Ishihara S; Asano Y; Watanabe M; Noda S; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2393-5. PubMed ID: 24394123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of bevacizumab with paclitaxel for advanced breast cancer - a case report].
    Morishita A; Mitsuhashi S; Fujisawa F; Hirano M; Kojima H
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):761-4. PubMed ID: 23863653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.